South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug ...

Real-Time Innovations (RTI) is the infrastructure software company for smart-world systems. RTI Connext ® is the world's leading software framework for intelligent distributed systems. Uniquely, ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic ...

ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash ...

Tevimbra plus chemotherapy was previously approved to treat advanced gastric and gastroesophageal junction cancers. Credit: Orawan Pattarawimonchai/Shutterstock. The ...

Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...

has approved TEVIMBRA ® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell ...

2 About TEVIMBRA ® (tislelizumab-jsgr) TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and ...